ABSTRACT
Clinical-grade T cells are genetically modified ex vivo to express a chimeric antigen receptor (CAR) to redirect specificity to a tumor associated antigen (TAA) thereby conferring antitumor activity in vivo. T cells expressing a CD19-specific CAR recognize B-cell malignancies in multiple recipients independent of MHC because the specificity domains are cloned from the variable chains of a CD19 monoclonal antibody. We now report a major step towards eliminating the need to generate patient-specific T cells by generating "universal" allogeneic TAA-specific T cells from one donor that might be administered to multiple recipients. This was achieved by genetically editing CD19-specific CAR + T cells to eliminate expression of the endogenous αβ T-cell receptor (TCR) to prevent a graft-versus-host response without compromising CAR-dependent effector functions. Genetically modified T cells were generated using the Sleeping Beauty system to stably introduce the CD19-specific CAR with subsequent permanent deletion of α or β TCR chains with designer zinc finger nucleases. We show that these engineered T-cells display the expected property of having redirected specificity for CD19 without responding to TCR stimulation. CAR + TCR neg T cells of this type may potentially have efficacy as an off-the-shelf therapy for investigational treatment of Blineage malignancies.
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INTRODUCTION
Allogeneic hematopoietic stem-cell transplantation (HSCT) can cure some patients with high risk B-cell leukemia/lymphoma, but relapse remains a major cause of death. To improve the graft-versus-leukemia/lymphoma (GVL)-effect, donor-derived T cells can be genetically modified to express a tumor-specific chimeric antigen receptor (CAR) with specificity derived from the variable domains of a monoclonal antibody, thus focusing immunoreactivity towards the tumor in an MHC non-restricted manner. 1 However, the endogenous αβ T-cell receptor (TCR) on infused allogeneic T cells may recognize major and minor histocompatibility antigens in the recipient leading to graft-versus-host-disease (GVHD). As a result, the majority of current clinical trials infuse autologous CAR + T-cells relying on immune tolerance to prevent TCR-mediated deleterious recognition of normal tissues after adoptive transfer. 2 This approach has achieved initial clinical successes targeting CD19 + malignancies, [3] [4] [5] [6] [7] but is limited by the time and expense to manufacture patient-specific T-cell products. Our goal is to generate off-the-shelf universal CAR + T cells from allogeneic healthy donors which can be administered to any patient without causing GVHD.
CD19 is constitutively expressed on most acute and chronic B-cell malignancies.
Therefore, to target malignant B cells, we have adapted the Sleeping Beauty (SB) transposon/transposase system for human application to stably express a CD19-specific CAR (designated CD19RCD28). [8] [9] [10] [11] SB modified CAR + T cells can be numerically expanded to clinically-sufficient numbers by the recursive addition of γ-irradiated artificial antigen presenting cells (aAPC) that co-express CD19 and desired T cell co-stimulatory molecules. 12, 13 These platforms have been adapted for human application as clinical trials based on the electroporation and propagation of CAR + T cells have achieved institutional and For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From federal regulatory approvals for the adoptive transfer of patient-derived and allogeneic CD19RCD28 + T cells after autologous and allogeneic HSCT (INDs #14193, 14577, 14739). 2, 8, 10, 11 To test the feasibility of using allogeneic CAR + T cells we modified the culturing process for generating CAR + T cells (Supplement Figure 1) to include the editing of the genome of CAR neg and CAR + T cells to irreversibly eliminate expression of the αβ TCR. To knockout the αβ TCR loci we employed zinc finger nucleases (ZFNs), 14 comprised of zinc finger protein DNA binding domains fused to the DNA cleavage domain from the Fok I endonuclease, targeting genomic sequences in the constant regions of the endogenous α or β subunits of the TCR. ZFNs mediate genome editing by catalyzing the formation of a DNA double strand break (DSB) in the genome. Targeting a DSB to a predetermined site within the coding sequence of a gene has been previously shown to lead to permanent loss of functional target gene expression via repair by non-homologous end joining (NHEJ), an errorprone cellular repair pathway that results in the insertion or deletion of nucleotides at the cleaved site. 15, 16 Here we demonstrate that ZFNs targeting either the α or β chains of endogenous TCRs in T cells resulted in the desired loss of TCR expression. As expected, these modified T cells did not respond to TCR stimulation, but maintained their CAR mediated re-directed specificity for CD19.
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MATERIALS AND METHODS

Human Subjects
Peripheral blood mononuclear cells (PBMC) were obtained from healthy adult volunteer donors who had provided informed consent from Gulf Coast Regional Center (Houston, TX).
Primary tumor cells were obtained after informed consent from patients at MD Anderson Cancer Center (MDACC) with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). Clinical research in accordance with the Declaration of Helsinki and approved by MDACC.
ZFNs targeting constant regions of α and β TCR
ZFNs containing 5 or 6 fingers were assembled from an established archive of pre-validated 2-finger and 1-finger modules as described. 17, 18 The ZFN pairs designed to bind either a sequence within exon 1 of the TCR α constant region (TRAC: NG_001332.2; ZFNs designated as TRAC-ZFN-1 and TRAC-ZFN-2) or a consensus sequence common to exon 1 of both TCR β constant regions 1 and 2 (TRBC1 and TRBC2: NG_001333.2; ZFNs designated as TRBC-ZFN-1 andTRBC-ZFN-2), will be described in detail elsewhere. 19 Genes encoding the ZFNs were assembled using PCR-based methodology and cloned into a DNA expression plasmid (pVAX; Invitrogen, Carlsbad, CA). These plasmids were linearized with XhoI and the RiboMAX Large Scale RNA Production System-T7 (Promega, Madison, WI) with ARCA cap analog (Ambion, Austin, TX) was used to produce and cap mRNA. After in vitro transcription poly-adenines were added using a poly A tailing kit (Ambion), the integrity and size of the mRNA species was validated on a denaturing 1% agarose gel with 3-(Nmorpholino) propanesulphonic acid (MOPS) buffer and concentration was measured using a spectrophotometer (BioRad, Hercules, CA) at OD 260 . The mRNA was stored at -80°C in nuclease-free vials for single use.
Flow cytometry
The following monoclonal antibodies (mAbs) and reagents were used with indicated specificity and the appropriate isotype controls. From BD Biosciences (San Jose, CA): 
Artificial antigen presenting cells
K562-derived aAPC were previously modified by lentiviral transduction to constitutively coexpress CD19, CD64, CD86, CD137L, membrane-bound (MB) IL-15 and EGFP (the latter For personal use only. on August 31, 2017. by guest www.bloodjournal.org From encoded following the EMCV IRES element). A clone (#4) was obtained by limiting dilution and numerically expanded for use. 20 For some experiments CD3-specific antibody (OKT3; eBioscience, San Diego, CA) was used to activate T cells by pulsing the mAb onto the CD64 + (FcR) clone #4 (Supplement Figure 2) . Expression of desired transgenes and bound OKT3 was validated weekly by flow cytometry before use in co-culture with T cells.
Propagation of primary T-cells
Healthy donor derived PBMC were isolated by density gradient separation using Ficoll-Paque Plus (GE Healthcare, Pittsburgh, PA). T cells were numerically expanded in the presence of 50 IU/mL of recombinant human interleukin-2 ([rhIL-2] added three time a week; Chiron, Emeryville, CA) on γ-irradiated (100 Gy) aAPC (clone #4, 1:2 T cell : aAPC ratio) that had been pre-loaded with OKT3. T cells with aAPC were cultured in complete medium (CM) defined as Hyclone-RPMI 1640 (Thermo Fisher Scientific, Waltham, MA) supplemented with 2 mmol/L L-glutamine (Glutamax-1: Invitrogen) and 10% heat-inactivated Hyclone-fetal bovine serum (Thermo Fisher Scientific).
Generation and Propagation of CAR + T cells
DNA supercoiled plasmids (15μg of CD19RCD28/pSBSO and 5μg of pKan-CMV-SB11) 13 encoding the SB transposon (to stably express CD19RCD28) and the SB transposase (to transiently express SB11) were electro-transferred using an Amaxa Nucleofector II device (Lonza, Basel, Switzerland) at 2 x 10 7 PBMC/cuvette as previously described (Supplement Figure 1 ). 12 T cells expressing CD19RCD28 were preferentially propagated in CM by recursive addition every 7 or 14 days of clone #4 (not loaded with OKT3) at 1:2 T-cell : aAPC (γ-irradiated to 100 Gy) ratio in the presence of rhIL-2 50 IU/mL, added three times a week.
Electro-transfer of messenger RNA species into primary or CAR + T cells
Six days after stimulation of unmodified T cells with OKT3-loaded clone #4 or 2 to 4 days after the last stimulation of CD19RCD28 + T-cells with clone #4, 5x10 6 T-cells were mixed with 2.5 to 10.0 μg of each ZFN mRNA in 100 μL of Human T-Cell Nucleofector solution (Cat #VPA-1002, Lonza) and electroporated using the Nucleofector II device with program T-20.
Following electroporation, cells were immediately placed in 2 mL of pre-warmed CM and cultured at 37ºC, 5% CO 2 for 4 to 6 hours and then 50 IU/mL of rhIL-2 was added with 2 mL of 20%FBS-RPMI. In some experiments to enhance ZFN-mediated enzymatic activity, after overnight culture, cells were transferred to 30ºC, 5% CO 2 and cultured for 2 days then returned to 37ºC-5% CO 2 .
Enrichment of CD3 neg T cells
Cells washed with PBS supplemented with 2% FBS and 2mM EDTA, were incubated for 10 minutes with CD3 microbeads (Cat # 130-050-101, MilteneyiBiotec, Auburn, CA) at 4°C. After washing twice, cells were passed through an LD column (Cat # 130-042-901, MilteneyiBiotec), and the flow-through fraction was collected for further use.
Surveyor Nuclease assay
The levels of genomic disruption of TRAC, TRBC1, and TRBC2 in T cells were determined by Surveyor Nuclease assay (Transgenomics, Omaha, NE) using CEL I nuclease. 21 The percent target disruption was quantified by densitometry. The PCR primers used for the amplification of target locus are:
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From TRBC2 forward, 5'-CCTGGCCACAGGCTTCTACC-3' TRBC2 reverse 5'-CCACCTTGTCCACTCTGGCTT-3'
Chromium release assay
Target cells were labeled with 0.1 mCi of 51 Cr (Perkin Elmer, Boston, MA) for 2 hours. After washing thrice with ice-cold CM, labeled cells were diluted and plated at 10 3 cells/well in 100 μL CM in 96-well v-bottomed plates. T-cells were added in 100 μL/well at indicated effector target ratios and the plate was spun (180 x g for 3minutes without brake) to facilitate cell-tocell contact. After 4 hours or 6 hours (when using primary tumor cells as targets) incubation at 37°C, 5%CO 2 , 50 μL of supernatants were counted on TopCount (Perkin Elmer, Shelton, CT). All assays were performed in triplicate. The percent specific lysis was calculated as follows: ((experimental cpm -spontaneous cpm) / (maximum cpm -spontaneous cpm)) × 100.
PKH-26 dilution assay
T-cells were incubated with 2.0 μM of the red-fluorescent lipophilic dye PKH-26 (Cat # PKH26GL, Sigma-Aldrich) for 5 minutes at room temperature according to the manufacturer's instructions. Cells, 100% labeled with PKH-26, were stimulated with either OKT3 loaded aAPC or CD19 + aAPC in CM supplemented with 50 IU/mL rhIL-2 (added every-other-day).
PKH-26-derived fluorescence was measured by flow cytometry 10 days after stimulation and CD19RCD28 + T cells were revealed using anti-CAR mAb clone 136-20-1.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From . Electro-transfer of mRNA to primary T cells was generally well-tolerated, though a slight reduction in cell viability was observed at higher doses. ZFN-mediated gene disruption has been reported to be more efficient when cells are transiently exposed to mild hypothermia. 22 Thus, we cultured T cells for 2 days at 30°C after electro-transfer. ZFNmediated disruption of CD3ε was up to 2.4-fold higher when electroporated T cells were cultured at 30°C versus 37°C. Using this approach, 37% and 15% of electroporated T-cells lost expression of CD3ε using the ZFN pair targeting TRAC and TRBC, respectively, (Figure   2b , lower panel) with no change in the levels of CD3 negative cells in the untransfected samples and without an appreciable decrease in viability (measured by Trypan blue).
RESULTS
Disruption of the αβ TCR-CD3 complex on T cells using ZFNs
To confirm that electroporated T cells had been genetically modified at the intended ZFN target sites (TCR α or β loci), a Surveyor Nuclease assay was performed using specific oligonucleotide primers flanking target sites within TRAC, TRBC1, or TRBC2. CEL I nuclease digestion products, representative of genetic changes induced by the ZFNs, were present only after electro-transfer of the TCR-specific ZFN pairs and the percent disruption assessed by densitometry correlated with loss of cell surface CD3ε expression (Figure 2c) . These experiments in primary T cells confirmed that ZFNs designed to target TRAC or TRBC lead to permanent disruption of αβTCR expression, as assessed by the CEL I-mediated surveyor nuclease assay and confirmed by flow cytometry analysis of CD3ε.
Enrichment of TCR neg T cells
For future clinical applications, rapid and robust methods for isolating sources of a TCRdisrupted population will be needed. To address this issue, we enriched the TCR/CD3 neg population by negative selection using paramagnetic beads and a depletion column. With a single depletion step, we enhanced the CD3ε neg population to over 93% (Figure 3a) . A CD3ε neg population could not be enriched from control T cells that were not genetically edited with ZFNs. Back-to-back CD3-depletion resulted in >99% enrichment without skewing the CD4 + or CD8 + T-cell subsets (Figure 3b) . The depletion of CD3 + T cells will also deplete remaining γδTCR + T cells. A flow cytometry analysis of TCR Vβ repertoire in enriched TCR neg T cells validated the elimination of TCRβ expression from the T-cell surface (Figure 3c ). This degree of depletion is clinically appealing as the loss of TCR on donor-derived T cells will prevent GVHD in HLA-disparate recipients.
Generation of TCR neg CAR + T cells by ZFNs
To test the ability of ZFN pairs to knock out TCR αβ expression from allogeneic CD19RCD28 + T cells, we initially genetically modified PBMC to stably express the CD19RCD28 CAR using the SB transposon/transposase system. The CD19RCD28 + T-cell population was specifically propagated by stimulating with γ-irradiated CD19 + aAPC (clone #4) every 7 days (Supplementary Figure 1b) . After four rounds of stimulation, we observed For personal use only. on August 31, 2017. by guest www.bloodjournal.org From over 90% CAR expression in T cells similar to our previously published results. 12 Within 2 to 4 days after the fifth stimulation with CD19 + aAPC, when T cells were activated, we electroporated the cells with mRNA encoding the TRAC or TRBC ZFNs (Figure 4a) . Flow cytometry analysis revealed that up to 30% and 26% of CD19RCD28 + T cells lost CD3ε expression after transfection of the TRAC or TRBC ZFNs, respectively (Figure 4b) . The CD3ε neg population was again readily enriched by paramagnetic beads, and the Surveyor Nuclease assay confirmed that the CD3ε neg population contained a high percentage of modified alleles at the intended ZFN target sites within the TRAC and TRBC loci (Figure 4c) .
The frequency of TRBC1 and TRBC2 disruption at the DNA level was approximately 20-25% and that of TRAC disruption was approximately 60%. These numbers fit with the observed frequencies of CD3ε neg CD19RCD28 + T cells because in each cell only 1 out of 4 TRBC alleles (2 TRBC1 and 2 TRBC2) is expressed. Similarly 1 of 2 TRAC alleles is expressed in each T cell. Therefore, disruption of the expressed allele is sufficient to achieve the CD3 negative phenotype.
TCR neg CAR + T cells do not respond to TCR stimulation, but do maintain CD19 specificity
We anticipated that TCR neg CAR + T cells could not respond to TCR stimulation. To test this, we measured the proliferative response of these cells after stimulation by cross-linking CD3 with OKT3 in comparison to activating CAR for sustained proliferation upon docking with CD19. TCR neg CD19RCD28 + T cells proliferated in response to CD19, but not OKT3 (Figure   5a ). Next, we assessed the ability of TCR neg CD19RCD28 + T cells to lyse CD19 + target cells in a standard 4-hour 51 Cr release assay (Figure 5b) . The capacity of TCR neg CAR + T cells to specifically lyse CD19 target cells was similar to that observed for TCR + CD19RCD28 + T cells.
Moreover, these TCR neg CAR + T cells maintain cytotoxicity against CD19 + primary tumors
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From (Figure 5c ). Together, these data confirmed that the absence of a measurable TCR on TCR neg CD19RCD28 + T cells corresponds with abrogation of TCR activity, but does not impact the ability of the CAR to activate genetically modified T cells for proliferation and target cell killing.
TCR neg CD19RCD28 + T-cells can be propagated on CD19 expressing aAPCs
We validated that CD19RCD28 + T cells sustain their proliferative capacity to expand to the cell numbers required for clinical applications. Both the TCR neg CD19RCD28 + and parental TCR + CD19RCD28 + T cells exhibited similar growth kinetics in response to stimulation with the CD19 + aAPC (Figure 6a) . We did not observe any changes in CD3ε expression on TCR neg CD19RCD28 + T cells after aAPC-mediated propagation (Figure 6b, top panel) . As predicted, these T cells failed to express TCRαβ on their cell surface (Figure 6b , middle panel and Figure 6c ). As expected, the ZFN-mediated disruption of αβTCR expression and depletion of CD3 + T cells led to loss of γδTCR + T cells (Figure 6b, middle panel) . After propagation on aAPC a subset of TCR neg CD19RCD28 + T cells exhibited memory phenotype based on expression of CD62L and absence of CD45RA 23 (Figure 6b , bottom panel) which may benefit persistence and thus the therapeutic potential of our approach to "off-the-shelf"
adoptive T-cell therapy. These data confirm that TCR neg CAR + T cells may be able to be propagated to achieve sufficient cell numbers from a single donor-derived modified T-cell pool for infusions into multiple recipients.
DISCUSSION
We have demonstrated that T cells and indeed CAR + T cells can be genetically edited by
ZFNs to eliminate expression of the endogenous αβ TCR. This has therapeutic implications where donor-derived T cells are infused to achieve an anti-tumor effect. Therapeutic success after allogeneic HSCT is defined as achieving a GVL-effect without causing clinicallysignificant GVHD. 24 Thus, separation of GVL and GVHD is a crucial issue following engraftment of allogeneic hematopoietic stem cells and strategies to accomplish this are based on infusing desired T-cell effector populations predicted to reduce unwanted allogeneic effects. This includes the adoptive transfer of donor-derived memory T cells employing a narrowed TCR Vβ repertoire compared with naïve T cells 25, 26 or in vitro depletion of T-cells activated through allo-antigens 27, 28, 29 . Adding to this approach, we have previously demonstrated that CAR + T cells expressing alloreactive TCRs can be rendered anergic to disparate HLA while maintaining specificity for CD19. 13 This was achieved by blockade of costimulatory molecules upon co-culture of genetically modified T cells with stimulator cells expressing disparate HLA. An alternative to pre-selection includes conditional ablation of infused allogeneic CAR + T cells in the event that serious adverse events occur. This has been accomplished by genetic modification of allogeneic T cells to express "suicide genes" such as thymidine kinase (TK), 30 iCasp9, 31 CD20, 32 thymidylate kinase, 33 and a modified Fas 34 that can be triggered for conditional ablation via the administration of specific molecules (e.g., ganciclovir to TK + expressing cells).
We recognized that approaches to selectively deplete T cells expressing undesired αβTCR may be incomplete and that complete knockout of the endogenous TCR might be advantageous to prevent GVHD. Therefore, we undertook a genetic approach using designer ZFNs to permanently disrupt the α and β constant region sequences in T cells thereby For personal use only. on August 31, 2017. by guest www.bloodjournal.org From eliminating TCR expression. Since TCR αβ receptors need to form heterodimers to express a functional cell surface molecule, knocking out either TRAC or TRBC was sufficient to eliminate TCR αβ expression. This is supported by a recent publication showing that a mutation in TRAC gene leads to the loss of TCR αβ expression. 35 ZFNs have been demonstrated to disrupt target gene expression as a consequence of error-prone DNA DSB repair by NHEJ, which in most cases results in a frame shift mutation leading to a premature stop of translation. 15 This technology is being evaluated in early stage clinical trials infusing HIV-resistant T cells generated by ZFN-mediated disruption of the CCR5 co-receptor for HIV-I. 16, 36 ZFNs target and thus disrupt gene expression at the genomic level which is an advantage over techniques that involve transcriptional repression and require sustained expression of the inhibiting factor (e.g., enforced expression of shRNA to mediate TCR down regulation 37 ). That ZFNs can permanently disrupt gene expression after transient expression (without the inherent dangers of genomic integration) enabled our use of in vitro transcribed mRNA species in a "hit-and-run" manner for electro-transfer of ZFNs into T cells.
The human application of "universal" CAR + T cells that have been genetically edited with ZNFs will depend on efficacy as well as safety. The genetically modified T cells specifically lysed primary targets and cell lines. Their therapeutic potential is also dependent on persistence after adoptive transfer. The 2 nd generation CAR chosen for this study activates T cells through chimeric CD28 and CD3-ζ. It remains to be determined in side-byside clinical trials if other CAR designs, such as signaling through CD137 and CD3-ζ are superior. Safety depends on selective elimination of endogenous TCR and minimizing ZFNmediated enzymatic activity at off-target sites. We evaluated the most likely "off-target" sites using CEL-I nuclease and did not detect cleavage. We did observe that the efficiency of For personal use only. on August 31, 2017. by guest www.bloodjournal.org From enzymatic activity at TRAC or TRBC genomic loci is approximately 20-40% after a single electro-transfer of mRNA species coding for ZFN pairs. However, continued cell surface expression of TCR from HLA-disparate candidate T-cell donors may cause GVHD after adoptive immunotherapy. Therefore, to prevent GVHD after infusion we used CD3-specific paramagnetic beads to deplete and re-deplete T cells with residual expression of TCR. This is a clinically appealing strategy as this approach can readily be undertaken in compliance with current good manufacturing practice for Phase I/II trials. Our planed clinical trials will include release criteria of the manufactured T-cell product based on residual αβTCR expression and an assessment of the maximum number of genetically modified T cells that can be safely infused from an allogeneic donor into multiple recipients. In addition, the wellbeing of the patients can also be safeguarded by co-expressing CAR with a transgene capable of mediating conditional T-cell ablation.
Previous reports suggest that T-cell activation mediated through an endogenous TCR
is required to obtain a fully functional CAR in a model system using Jurkat cell lines 38 . In contrast, we observed that knocking out TCR αβ expression from CD19RCD28 + T cells did not appreciably alter the ability of these cells to specifically kill CD19 + targets or proliferate in response to CD19. One reason for this discrepancy other than the difference in host cells may be the use of a 2 nd generation CAR, which includes signaling not only through CD3ζ (signal 1) but also CD28 (signal 2; co-stimulation). [39] [40] [41] A benefit to expressing a TCR with known specificity is that activation through the endogenous immunoreceptor can be used to propagate T cells to achieve an anti-tumor effect mediated by the CAR. 42, 43 It remains to be tested in humans whether coordinated co-stimulation achieved through multiple CAR signaling endodomains will be sufficient to sustain persistence in vivo or if triggering of T cells through TCR is needed. However, the propagation of CD19RCD28 + T cells on aAPC For personal use only. on August 31, 2017. by guest www.bloodjournal.org From modified to co-express CD19 along with co-stimulatory molecules results in the significant expansion of CAR + memory T-cell subsets predicted to have prolonged in vivo survival. 44, 45 Therefore, any loss of persistence of TCR neg CD19RCD28 + T cells may be off-set by costimulatory properties of aAPC and the encoded CD28 intra-cellular domain within the CAR.
Preparing antigen-specific T cells from a third-party donor is clinically appealing as these products can be generated, stored and validated before use and infused to multiple patients immediately as needed. 46 Indeed, third-party T cells have been successfully infused into patients with post-transplantation lymphoproliferative diseases. 47, 48 Despite the fact that a majority of the viral-antigen specific TCRαβ chains demonstrate cross-reactivity to allo-HLA in vivo, 49 clinically significant GVHD was not observed. This may be in part due to the ex vivo repetitive antigen stimulation resulting in the emergence of either an oligoclonal or monoclonal TCRαβ repertoire which decreases the chance of T-cell alloreactivity. On the contrary, when we numerically expand CD19RCD28 + T cells through in vitro CD19 stimulation on γ-irradiated aAPC independent of TCR stimulation we did not observe skewing of the TCR Vβ usage as assessed by a panel of Vβ-specific antibodies.
In conclusion, we demonstrate that TCR neg CAR + T cells can be generated using a 
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Functional consequences of ZFN-mediated TCR knockout in CAR + T cells a. Loss of responsiveness of TCR neg CAR + T cells to TCR stimulation
Dilution of PKH26 was measured 10 days after stimulation with aAPC loaded with OKT3 
c. Cytotoxicity by TCR neg CAR + T cells against CD19 + primary B-cell tumors
Propagation of TCR neg CAR + T cells on CD19 expressing aAPC a. Sustained proliferation of TCR neg CAR + T cells
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From CAR + T cells with (TRAC and TRBC) or without (parental and no mRNA) TCR modification by ZFNs were stimulated with γ-irradiated CD19 + aAPC every 2 weeks. Viable T cells were enumerated every 7 days and inferred total numbers were calculated. Representative data from 3 independent experiments is shown. 
b. Analysis of TCR neg CAR + T cells after propagation
